Physician profile
Benjamin Wollett
NPI 1780114470
$6,687.20
in general payments reported to CMS, 2019-2025
21 companies · $725 in 2025
The $725 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $617 · 2021: $2,206 · 2022: $1,435 · 2023: $903 · 2024: $801 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,428.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $2,827.55 | 2020-2025 | Asnis, N/A, Anchorage |
| Medinc of Texas | $1,212.23 | 2021-2022 | |
| Smith+Nephew, INC. | $1,121.44 | 2020-2025 | Grafix Pl, Stravix Pl, Collagenase Santyl |
| Paratek Pharmaceuticals, INC. | $360.72 | 2021-2025 | Nuzyra |
| Organogenesis INC. | $235.45 | 2022-2025 | Puraply, Affinity, Nushield |
| Medline Industries LP | $171.81 | 2022-2023 | |
| Horizon Therapeutics Plc | $156.15 | 2021-2023 | Krystexxa |
| Grt US Holding, INC. | $112.49 | 2022 | |
| Treace Medical Concepts, INC. | $107.87 | 2024-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $71.23 | 2021-2023 | Jublia |
| Amgen INC. | $60.81 | 2024-2025 | Krystexxa |
| Acera Surgical, INC. | $36.31 | 2020-2021 | |
| Kerecis Limited | $33.06 | 2020-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Melinta Therapeutics, LLC | $31.25 | 2022 | |
| Medtronic, INC. | $29.93 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kci USA, INC. | $28.76 | 2020 | |
| Fidia Pharma USA INC. | $22.01 | 2020 | |
| Hydrofera LLC | $20.23 | 2023 | Hydrofera Blue |
| Biocomposites INC | $18.34 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $17.05 | 2022 | |
| Nabriva Therapeutics, Plc | $12.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Wollett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.